Neumentum Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $10M

  • Investors
  • 8

Neumentum General Information

Description

Developer of a pharmaceutical platform intended to offer non-opioid pain therapeutics to patients. The company's platform offers four non-opioid drug candidates in development, from different assets to novel chemical entities, in both hospital and retail markets for acute and chronic pain indications, enabling patients to have options for viable non-opioid analgesics that can effectively treat their moderately severe pain.

Contact Information

Website
www.neumentum.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 350 Springfield Avenue
  • Suite 200
  • Summit, NJ 07901
  • United States
+1 (833) 000-0000
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • 350 Springfield Avenue
  • Suite 200
  • Summit, NJ 07901
  • United States
+1 (833) 000-0000

Neumentum Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neumentum Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A2) 08-Nov-2023 $10M 000.00 00000 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series A2) 27-Apr-2023 0000 000.00 00000 Completed Clinical Trials - Phase 3
3. Early Stage VC (Series A2) 31-May-2021 000.00 000.00 0000 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series A1) 30-May-2018 $7.31M $13.3M 0000 Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 01-Nov-2017 $6M $6M 0000 Completed Startup
To view Neumentum’s complete valuation and funding history, request access »

Neumentum Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-2/A 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A-2/B 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A1 6,210,333 $0.001000 $1.18 $1.18 1x $1.18 8.33%
Series A 6,000,000 $0.001000 $1 $1 1x $1 8.05%
To view Neumentum’s complete cap table history, request access »

Neumentum Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a pharmaceutical platform intended to offer non-opioid pain therapeutics to patients. The company's platfor
Drug Discovery
Summit, NJ
6 As of 2024
000.00
00000 0000-00-00
00000000000 000.00

000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
000000000000000
Bay Harbor Islands, FL
0 As of 0000
000.00
00000000 000.00

000000

ion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dol
000000000000000
Tampa, FL
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neumentum Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avenue Therapeutics Corporation Bay Harbor Islands, FL 0 000.00 00000000 000.00
Pacira BioSciences Formerly VC-backed Tampa, FL 000 00000 000000000 00000
Heron Therapeutics Formerly VC-backed San Diego, CA 000 00000 000000000 00000
Mallinckrodt Formerly PE-Backed Dublin, Ireland 0000 00.00 0000000000.
To view Neumentum’s complete competitors history, request access »

Neumentum Patents

  • 3

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Neumentum Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4136072-A1 Compositions and methods for treating pain and/or inflammation Pending 15-Apr-2020 0000000000 0
US-20220008390-A1 Compositions and methods for treating pain and/or inflammation Inactive 15-Apr-2020 0000000000 0
EP-4136072-A4 Compositions and methods for treating pain and/or inflammation Pending 15-Apr-2020 C07D231/14 0

Neumentum Executive Team (8)

Name Title Board Seat
Robert Raffa Ph.D Chief Scientific Officer
Sarah Faust Chief Commercial Officer
Joseph Pergolizzi MD Founder and Executive Chairman
Joseph Scavone Head of Clinical Operations and Regulatory Affairs
You’re viewing 4 of 8 executive team members. Get the full list »

Neumentum Board Members (6)

Name Representing Role Since
Andrew Blank Self Board Member 000 0000
August Moretti JD Self Board Member 000 0000
Joseph Pergolizzi MD Neumentum Founder and Executive Chairman 000 0000
You’re viewing 3 of 6 board members. Get the full list »

Neumentum Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neumentum Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Global Equity Ventures Venture Capital Minority 000 0000 000000 0
AngelMD Angel Group Minority 000 0000 000000 0
Green Park & Golf Ventures Venture Capital Minority 000 0000 000000 0
David Hunt Angel (individual) Minority 000 0000 000000 0
Evolution VC Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Neumentum FAQs

  • When was Neumentum founded?

    Neumentum was founded in 2017.

  • Who is the founder of Neumentum?

    Joseph Pergolizzi MD, Scott Shively, and Christine Mikail JD are the founders of Neumentum.

  • Where is Neumentum headquartered?

    Neumentum is headquartered in Summit, NJ.

  • What is the size of Neumentum?

    Neumentum has 6 total employees.

  • What industry is Neumentum in?

    Neumentum’s primary industry is Drug Discovery.

  • Is Neumentum a private or public company?

    Neumentum is a Private company.

  • What is the current valuation of Neumentum?

    The current valuation of Neumentum is 00000.

  • What is Neumentum’s current revenue?

    The current revenue for Neumentum is 00000.

  • How much funding has Neumentum raised over time?

    Neumentum has raised $55.6M.

  • Who are Neumentum’s investors?

    Global Equity Ventures, AngelMD, Green Park & Golf Ventures, David Hunt, and Evolution VC Partners are 5 of 8 investors who have invested in Neumentum.

  • Who are Neumentum’s competitors?

    Avenue Therapeutics, Pacira BioSciences, Heron Therapeutics, and Mallinckrodt are competitors of Neumentum.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »